- Home
- BDTX vs DOUG Comparison
BDTX vs DOUG Comparison
Compare BDTX & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | DOUG |
|---|---|---|
| Founded | 2014 | 1911 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 178.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BDTX | DOUG |
|---|---|---|
| Price | $2.11 | $1.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 607.8K | 340.8K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | 118.68 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $955,578,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $1.53 |
| 52 Week High | $4.94 | $3.19 |
Technical Indicators
Market Signals| Indicator | BDTX | DOUG |
|---|---|---|
| Relative Strength Index (RSI) | 63.89 | 54.97 |
| Support Level | $2.13 | $1.70 |
| Resistance Level | $2.26 | $2.10 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 86.92 | 54.44 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.